piperidines and Scleritis

To assess the efficacy of biologic drugs, beyond tumor necrosis factor- (TNF-). Fourteen patients (19 eyes) were enrolled in the study. Scleritis inflammatory grading significantly improved from baseline to 3 months (. Our results, though limited to a low number of patients, highlight the effectiveness of different biologic therapies in the treatment of noninfectious refractory scleritis, showing to control scleral inflammation and allowing a significant reduction in the number of relapses.

Topics: Abatacept; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Female; Humans; Immune System; Inflammation; Interleukin 1 Receptor Antagonist Protein; Male; Middle Aged; Ophthalmology; Piperidines; Pyrimidines; Recurrence; Retrospective Studies; Rituximab; Scleritis; Treatment Outcome

A 65-year-old male presented with redness and pain associated with active necrotizing scleritis in the left eye. He was started on mycophenolate mofetil and oral corticosteroids, to which there was no response detected after 4 weeks. A rheumatology opinion was sought and he was started on tofacitinib, after which there was dramatic clinical improvement. Patients refractory to conventional immunosuppressive therapy can benefit from the new class of immunosuppressive agents, JAK/STAT kinase inhibitors.

Topics: Aged; Humans; Immunosuppressive Agents; India; Male; Piperidines; Pyrimidines; Pyrroles; Scleritis